Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia

OBJECTIVES: Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous beta-thalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of defera...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Al-Khabori, Murtadha, Bhandari, Sunil, Al-Huneini, Mohammed, Al-Farsi, Khalil, Panjwani, Vinodh, Daar, Shahina
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: OMJ 2013
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3628199/
https://ncbi.nlm.nih.gov/pubmed/23599881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5001/omj.2013.31
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia